Shares of Atossa Genetics Inc (NASDAQ:ATOS) saw unusually-high trading volume on Tuesday . Approximately 12,858,374 shares changed hands during trading, an increase of 356% from the previous session’s volume of 2,818,392 shares.The stock last traded at $3.48 and had previously closed at $2.83.

ATOS has been the topic of several recent research reports. ValuEngine upgraded Atossa Genetics from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 15th. Maxim Group restated a “buy” rating and issued a $5.00 price target on shares of Atossa Genetics in a research report on Wednesday, January 9th.

The stock has a market capitalization of $25.82 million, a P/E ratio of -0.63 and a beta of 3.82.

An institutional investor recently raised its position in Atossa Genetics stock. Virtu Financial LLC increased its stake in Atossa Genetics Inc (NASDAQ:ATOS) by 405.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 69,903 shares of the company’s stock after purchasing an additional 56,064 shares during the period. Virtu Financial LLC owned approximately 1.24% of Atossa Genetics worth $71,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 8.59% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was first published by Marea Informative and is the sole property of of Marea Informative. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at

Atossa Genetics Company Profile (NASDAQ:ATOS)

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

Featured Article: What is a bull market?

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with's FREE daily email newsletter.